Everything below concerns PPAR delta. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Kidnapping for extortion and political purposes Simple kidnapping According to data from the Directorate of Justice and Security of the DNP, this phenomenon shows an increasing trend. With respect to the costs of sequestration, the sources suggest an increasing behavior between 1996 and 2003, such that "the average annual growth rate is 9.3%, the highest rate is observed in 1998 (46.2%), and in 2000 (37.2%) year in which the number of kidnappings also it is significantly high [...] reaching its peak in the year 2000 with 1,938 cases." From then on, the trend decreases, except for a peak in 2002 with 1,542 cases, until reaching 350 kidnappings in 2005 (the lowest figure since 1996). Within these costs, 64.4% are direct, representing US$167.4 million. 35.6% of the remaining costs are indirect, and represent US$92.7 million. In 2004, the costs of sequestration were reduced to $109,519 million, representing 0.27% of GDP in 2003.
Stanley Adams, Roche's World Product Manager in Basel, contacted the European Economic Community in 1973 with evidence that Roche had been breaking antitrust laws, engaging in price fixing and market sharing for vitamins with its competitors. Roche was fined accordingly, but a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. He was arrested for unauthorised disclosure — an offence under Swiss law — and imprisoned. His wife, having learnt that he might face decades in jail, committed suicide. In 1999 the firm pleaded guilty to participation in a worldwide conspiracy to raise and fix prices for vitamins sold in the US and globally. Hoffmann-La Roche paid $500 million in criminal fines to the United States.
In certain cases, elderly patients' previous interactions with phenothiazine derivatives or pre-existing neuroleptic treatment may have contributed to dyskinesia at the administration of hydroxyzine due to hypersensitivity caused by prolonged treatment, and therefore some contraindication is given for short-term administration of hydroxyzine to those with previous phenothiazine use.
Sources: en.wikipedia.org
== Contribution in modern medicine == Quinine, which is found naturally in the bark of the cinchona tree, is known to be used by Quechuas people for malaria-like symptoms. When chewed, coca acts as a mild stimulant and suppresses hunger, thirst, pain, and fatigue; it is also used to alleviate altitude sickness. Coca leaves are chewed during work in the fields as well as during breaks in construction projects in Quechua provinces. Coca leaves are the raw material from which cocaine, one of Peru's most historically important exports, is chemically extracted.
The Mini DisplayPort connector was developed by Apple for use in their computer products. It was first announced in October 2008 for use in the new MacBooks and Cinema Display. In 2009, VESA adopted it as an official standard, and in 2010 the specification was merged into the main DisplayPort standard with the release of DisplayPort 1.2. Apple freely licenses the specification to VESA. The Mini DisplayPort (mDP) connector is a 20-pin single-orientation connector with a friction lock. Unlike the full-size connector, it does not have an option for a mechanical latch. The mDP receptacle has dimensions of 7.50 mm (width) × 4.60 mm (height) × 4.99 mm (depth). The mDP pin assignments are the same as the full-size DisplayPort connector.
== Career == Chilkoti joined Duke University in 1996 as an assistant professor of biomedical engineering. He was promoted to associate professor in 2002 and professor in 2006. He was the Theo Pilkington Chair Professor of Biomedical Engineering from 2008 to 2013, and has been the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke University since 2013. From 2002 till 2007, Chilkoti served as associate director of the Center for Biologically Inspired Materials and Material Systems at Duke University and was the director of the center from 2007 to 2011. In 2014, he became Chair of the Department of Biomedical Engineering at Duke University and served as chair until 2022. As Chair of the Duke BME department, he launched an incubator—BRiDGE—for Biomedical Engineering faculty and student startups, and he created the Duke Engineering Entrepreneurship program (DEEP)—a post-doctoral fellowship program for recent PhD graduates of the department interested in entrepreneurship. Since 2023, he has been serving as the senior associate dean of Pratt School of Engineering at Duke University. Chilkoti founded two Gordon Research Conferences (GRCs)—one on Biointerface Science in 2006 and a second on Bioinspired Materials in 2012. Furthermore, he is the founder of five start-ups.
Sources: en.wikipedia.org
In 1970, she began research at the Indian Institute of Technology, Kanpur (IIT Kanpur). In that year, she married Subramania Ranganathan, with whom she would go on to author Challenging problems in organic reaction mechanisms (1972), Art in biosynthesis: the synthetic chemist's challenge (1976), and Further challenging problems in organic reaction mechanisms (1980)—as well as editing an ongoing series titled "Current Organic Chemistry Highlights". She continued her research at IIT Kanpur on the basis of fellowships. Unwritten rules prevented her from joining the faculty because her husband was already a member. She began work at Regional Research Laboratory, Trivandrum in 1993, and at IICT, Hyderabad in 1998., where she became Deputy Director. During these years, she conducted ongoing collaborations with Isabella Karle at the U.S. Naval Research Laboratory. Darshan Ranganathan was diagnosed with breast cancer in 1997, and died on her 60th birthday, in 2001. The biennial "Professor Darshan Ranganathan Memorial Lecture", which is to be "delivered by a woman scientist who has made outstanding contributions in any field of Science and Technology" was established in her memory by her husband, in 2001.
During the initial 4 to 6 hours following the power change, the magnitude and the rate of change of concentration is dependent upon the initial power level and on the amount of change in power level; the 135Xe concentration change is greater for a larger change in power level. When reactor power is decreased, the process is reversed. Iodine-135 is a fission product of uranium with a yield of about 6% (counting also the 135I produced almost immediately from decay of fission-produced tellurium-135). This 135I decays with a 6.58 hour half-life to 135Xe. Thus, in an operating nuclear reactor, 135Xe is being continuously produced. 135Xe has a very large neutron absorption cross-section, so in the high-neutron-flux environment of a nuclear reactor core, the 135Xe soon absorbs a neutron and becomes effectively stable 136Xe. (The half-life of 136Xe is >1021 years, and it is not treated as a radioisotope.) Thus, in about 50 hours, the 135Xe concentration reaches equilibrium where its creation by 135I decay is balanced with its destruction by neutron absorption. When reactor power is decreased or shut down by inserting neutron-absorbing control rods, the reactor neutron flux is reduced and the equilibrium shifts initially towards higher 135Xe concentration. The 135Xe concentration peaks about 11 hours after reactor power is decreased. Since 135Xe has a 9.14 hour half-life, the 135Xe concentration gradually decays back to low levels over 72 hours.
== History == Insulin was discovered by Sir Frederick G Banting, Charles H Best, and JJR Macleod from the University of Toronto in 1921 as an injectable agent. German researchers first introduced the idea of inhalable insulin in 1924. Years of failure followed until scientists realized they might be able to use new technologies to turn insulin into a concentrated powder with particles sized for inhalation. In the 1980s Nektar Therapeutics, based on work by A. Carl Leopold on vitrifying proteins, developed technology to make insulin into small particles, technology then licensed to Pfizer. Alkermes developed a delivery device that they licensed to Eli Lilly and Company. Once concrete methods were developed, human tests began in the late 1990s. In January 2006, the U.S. Food and Drug Administration (FDA) approved the use of Exubera, a form of inhalable insulin developed by Pfizer. It was approved in the UK in August 2006 but reimbursed by the National Health Service only for people who had problems with needles. It was not reimbursed by any U.S. insurer. A 2007 systematic review concluded that the inhaled hexameric insulin (Exubera) "appears to be as effective, but no better than injected short-acting insulin. The additional cost is so much more that it is unlikely to be cost-effective." In 2007, Pfizer announced that it would no longer manufacture or market Exubera. According to Chairman and CEO Jeffrey Kindler this was because Exubera "failed to gain acceptance among patients and physicians".
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.